CO2021017343A2 - Formas de sales cristalinas de un inhibidor de cinasas - Google Patents
Formas de sales cristalinas de un inhibidor de cinasasInfo
- Publication number
- CO2021017343A2 CO2021017343A2 CONC2021/0017343A CO2021017343A CO2021017343A2 CO 2021017343 A2 CO2021017343 A2 CO 2021017343A2 CO 2021017343 A CO2021017343 A CO 2021017343A CO 2021017343 A2 CO2021017343 A2 CO 2021017343A2
- Authority
- CO
- Colombia
- Prior art keywords
- kinase inhibitor
- salt forms
- crystalline salt
- relates
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
RESUMEN La presente invención está relacionada con las formas cristalinas de sales del Compuesto 1. La invención también está relacionada con composiciones farmacéuticas que comprenden las sales cristalinas sólidas del Compuesto 1. La invención está relacionada además con métodos de tratamiento de una enfermedad, un trastorno o un síndrome mediado al menos en parte por la modulación de la actividad in vivo de una proteína cinasa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856404P | 2019-06-03 | 2019-06-03 | |
| PCT/US2019/065980 WO2020247019A1 (en) | 2019-06-03 | 2019-12-12 | Crystalline salt forms of a kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021017343A2 true CO2021017343A2 (es) | 2022-01-17 |
Family
ID=69160360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0017343A CO2021017343A2 (es) | 2019-06-03 | 2021-12-16 | Formas de sales cristalinas de un inhibidor de cinasas |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230052703A1 (es) |
| EP (1) | EP3976587A1 (es) |
| JP (1) | JP2022535072A (es) |
| KR (1) | KR20220016117A (es) |
| CN (1) | CN113939503B (es) |
| AU (1) | AU2019449809A1 (es) |
| BR (1) | BR112021024300A2 (es) |
| CA (1) | CA3139148A1 (es) |
| CL (1) | CL2021003205A1 (es) |
| CO (1) | CO2021017343A2 (es) |
| CR (1) | CR20210616A (es) |
| DO (1) | DOP2021000236A (es) |
| GE (1) | GEP20247655B (es) |
| IL (1) | IL288484A (es) |
| MA (1) | MA56001A (es) |
| MX (1) | MX2021014773A (es) |
| PE (1) | PE20220962A1 (es) |
| SG (1) | SG11202111978VA (es) |
| WO (1) | WO2020247019A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL300824A (en) * | 2018-01-26 | 2023-04-01 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| PE20211757A1 (es) * | 2018-12-13 | 2021-09-07 | Exelixis Inc | Formas cristalinas y formas de sal de un inhibidor de cinasa |
| AR127561A1 (es) * | 2021-11-03 | 2024-02-07 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
| WO2023122739A1 (en) | 2021-12-22 | 2023-06-29 | Exelixis, Inc. | Crystalline forms and salt forms of a kinase inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2612853A1 (en) * | 2003-09-26 | 2013-07-10 | Exelixis Inc. | c-Met modulators and methods of use |
| US7314622B2 (en) | 2005-04-15 | 2008-01-01 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| CN104994873B (zh) | 2012-10-04 | 2017-12-22 | 达纳－法伯癌症研究所公司 | 人单克隆抗‑pd‑l1抗体和使用方法 |
| SG11201508528TA (en) | 2013-05-02 | 2015-11-27 | Anaptysbio Inc | Antibodies directed against programmed death-1 (pd-1) |
| US20180009758A1 (en) * | 2015-06-29 | 2018-01-11 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
| CA3060370A1 (en) * | 2017-05-26 | 2018-11-29 | Exelixis, Inc. | Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| IL300824A (en) | 2018-01-26 | 2023-04-01 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| CN109761899B (zh) * | 2019-02-14 | 2022-11-15 | 广州六顺生物科技股份有限公司 | 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物 |
-
2019
- 2019-12-12 AU AU2019449809A patent/AU2019449809A1/en active Pending
- 2019-12-12 KR KR1020217041796A patent/KR20220016117A/ko unknown
- 2019-12-12 GE GEAP201915849A patent/GEP20247655B/en unknown
- 2019-12-12 JP JP2021571744A patent/JP2022535072A/ja active Pending
- 2019-12-12 WO PCT/US2019/065980 patent/WO2020247019A1/en active Application Filing
- 2019-12-12 EP EP19836340.0A patent/EP3976587A1/en active Pending
- 2019-12-12 MA MA056001A patent/MA56001A/fr unknown
- 2019-12-12 PE PE2021002015A patent/PE20220962A1/es unknown
- 2019-12-12 US US17/616,124 patent/US20230052703A1/en active Pending
- 2019-12-12 SG SG11202111978VA patent/SG11202111978VA/en unknown
- 2019-12-12 MX MX2021014773A patent/MX2021014773A/es unknown
- 2019-12-12 CN CN201980097028.2A patent/CN113939503B/zh active Active
- 2019-12-12 CR CR20210616A patent/CR20210616A/es unknown
- 2019-12-12 BR BR112021024300A patent/BR112021024300A2/pt unknown
- 2019-12-12 CA CA3139148A patent/CA3139148A1/en active Pending
-
2021
- 2021-11-17 DO DO2021000236A patent/DOP2021000236A/es unknown
- 2021-11-28 IL IL288484A patent/IL288484A/en unknown
- 2021-12-02 CL CL2021003205A patent/CL2021003205A1/es unknown
- 2021-12-16 CO CONC2021/0017343A patent/CO2021017343A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GEP20247655B (en) | 2024-08-26 |
| CN113939503A (zh) | 2022-01-14 |
| EP3976587A1 (en) | 2022-04-06 |
| SG11202111978VA (en) | 2021-11-29 |
| CN113939503B (zh) | 2024-05-07 |
| AU2019449809A1 (en) | 2021-12-16 |
| US20230052703A1 (en) | 2023-02-16 |
| IL288484A (en) | 2022-01-01 |
| BR112021024300A2 (pt) | 2022-01-11 |
| MA56001A (fr) | 2022-04-06 |
| DOP2021000236A (es) | 2022-04-18 |
| JP2022535072A (ja) | 2022-08-04 |
| CA3139148A1 (en) | 2020-12-10 |
| PE20220962A1 (es) | 2022-06-10 |
| WO2020247019A1 (en) | 2020-12-10 |
| CR20210616A (es) | 2022-03-22 |
| KR20220016117A (ko) | 2022-02-08 |
| MX2021014773A (es) | 2022-01-18 |
| CL2021003205A1 (es) | 2022-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021017343A2 (es) | Formas de sales cristalinas de un inhibidor de cinasas | |
| CL2021001537A1 (es) | Formas cristalinas y formas de sal de un inhibidor de cinasa | |
| CO2020006009A2 (es) | Métodos de uso de inhibidores de ehmt2 para tratar o prevenir trastornos sanguíneos | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| CO2020016582A2 (es) | Sales de sepiapterina farmacéuticamente aceptables | |
| EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
| UY38613A (es) | Inhibidores de la proteína tirosina fosfatasa y mètodos de uso de los mismos | |
| EA202092490A1 (ru) | Модуляторы метилмодифицирующих ферментов, композиции и их применения | |
| WO2016172496A8 (en) | Lsd1 inhibitors and uses thereof | |
| CL2022003360A1 (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados (divisional de la solicitud 202002578) | |
| NI202100018A (es) | Moduladores de la expresión de pnpla3 | |
| CL2023001268A1 (es) | Composiciones farmacéuticas de un inhibidor de cinasa | |
| CL2021002309A1 (es) | Compuestos útiles en la terapia del vih | |
| CL2021003455A1 (es) | Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida | |
| CO2021001277A2 (es) | Inhibidores de triazol glicolato oxidasa | |
| CO2021011042A2 (es) | Sales de sulcardina | |
| CU20220024A7 (es) | Compuestos aromáticos bicíclicos derivatizados por ácido fenilacético y bencilamina, útiles en el tratamiento de trastornos inmunológicos, enfermedades del sistema nervioso central, neurodegenerativas, renales y cardiovasculares | |
| EA202091003A1 (ru) | Новые производные пиразолопирролопиримидиндиона в качестве ингибиторов p2x3 | |
| ECSP22001370A (es) | Inhibidores de prmt5 | |
| BR112022024700A2 (pt) | Inibidores de atr e usos dos mesmos | |
| BR112022014278A2 (pt) | Conjugados de composto proteico-antiviral | |
| DOP2019000194A (es) | Derivados de pirrolotriazina como inhibidor de cinasas | |
| PE20200749A1 (es) | Moduladores de la expresion de enac | |
| CL2020001089A1 (es) | Compuestos inhibidores de tirosina cinasa de bruton (btk). | |
| EA202191653A1 (ru) | Кристаллические формы и солевые формы ингибитора киназы |